-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau pancreatic cancer Alpha DaRT pooled data accepted for ASCO presentation

PUBT·04/27/2026 13:02:51
Listen to the news
Alpha Tau pancreatic cancer Alpha DaRT pooled data accepted for ASCO presentation
  • Alpha Tau flagged acceptance of an ASCO Annual Meeting abstract covering pooled safety and efficacy results from three prospective studies of Alpha DaRT in advanced pancreatic cancer.
  • Results have not been presented yet; abstract publication is scheduled for May 21, 2026, with conference presentation during May 29–June 2, 2026.
  • Pooled analysis indicates treatment can be delivered using an endoscopic ultrasound-guided intratumoral approach with an overall profile that supports further development.
  • Company positioned dataset as strengthening clinical evidence base for pancreatic cancer, a key strategic focus for Alpha DaRT expansion.
  • Alpha Tau highlighted ongoing pipeline execution, citing continued progress in its US IMPACT trial combining Alpha DaRT with chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-047783), on April 27, 2026, and is solely responsible for the information contained therein.